polyarticular juvenile idiopathic arthritis
Rheumatology · 2010–2019
3decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tocilizumab Treatment of severe active polyarticular juvenile idiopathic arthritis (JIA). The submission sought to extend the listing of subcutaneous tocilizumab to match… | Mar 2019 | Recommended with restriction | none received |
| tocilizumab Treatment of active polyarticular course juvenile idiopathic arthritis (JIA) as a single-agent or in combination with methotrexate in patients 2 years of age… | Nov 2013 | Recommended with restriction | no section in document |
| adalimumab Treatment of severe active polyarticular course juvenile idiopathic arthritis in patients aged 4 years and older, either in combination with methotrexate or as… | Mar 2010 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.